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Background and purpose: COPD is one of the leading causes of morbidity and mortality 
worldwide. Although medication counseling interventions by pharmacists have been found to 
support the management of COPD, little is known about pharmacists’ knowledge concerning 
COPD and regular practices and perceptions concerning medication counseling of COPD 
patients. The purpose of this study was to research these topics among Finnish community 
pharmacists.
Materials and methods: In January 2017, an electronic survey was e-mailed to Finnish com-
munity pharmacies (n=741) via the Association of the Finnish Pharmacies. One pharmacist from 
each pharmacy, preferably a specialist in asthma, was invited to answer the survey.
Results: Completed responses were received from 263 pharmacists (response rate =35%), of 
whom 196 pharmacists were specialists in asthma. Response rate among asthma pharmacists 
was 42%. Pharmacists were positive about their role in medication counseling and in support of 
the self-management of COPD patients. COPD-related knowledge was self-assessed as being 
good and was on a good level in respect of basic facts. However, almost half (46%) of the phar-
macists did not know that COPD is considered a national public health issue, and ~50% of the 
pharmacists were not familiar with the current care guideline on COPD. Medication counseling 
was found to be more medicinal product-driven and less advisory concerning lifestyle changes 
such as smoking cessation and physical exercise.
Conclusion: Although the pharmacists’ knowledge of COPD was good on general topics, 
there were some gaps in their knowledge on the current care guideline and status of the disease. 
Pharmacists should more systematically individually target medication counseling according 
to patients’ needs. In addition, lifestyle treatments, including smoking cessation and physical 
exercise, should be part of the medication counseling.
Keywords: pulmonary disease, medication counseling, pharmacists, clinical practice guideline, 
knowledge
Introduction
COPD is one of the leading causes of morbidity and mortality worldwide, and in 
Western societies, the prevalence of COPD is mostly related to smoking.1 However, 
between 1990 and 2010, the total number of COPD deaths was decreasing globally 
in all age-groups.2 In Finland, the prevalence of COPD is between 3.7% and 9%, and 
COPD is recognized as an important public health issue by the National Institute of 
Health and Welfare.3–7
According to the global strategy for diagnosis, management, and prevention of 
COPD and several European guidelines, diagnostics of COPD should be improved.1,8–11 
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Lifestyle changes such as smoking cessation and physical 
exercising are important nonpharmacological ways of 
treating COPD. COPD medicines are used to relieve symp-
toms, such as dyspnea and to prevent exacerbations.1,8–11 
Appropriate nutrition and nutrition counseling based on the 
patient’s individual needs should be part of treatment,8,9 and 
influenza and pneumococcal vaccines are recommended for 
COPD patients.1,8–11
The role of pharmacists has been recognized in the treat-
ment of COPD patients, including actions from primary 
prevention (eg, educational campaigns), through prelimi-
nary diagnostics (eg, microspirometry testing), to ongoing 
support and follow-up of patients and their medications.6 
Special medication counseling interventions by community 
pharmacists are found to have a positive impact on patient 
and treatment outcomes among COPD patients.7–9 Two inter-
ventions in the Netherlands identified that active medication 
counseling by community pharmacists was a contributing 
factor in reducing drug-related problems and improving the 
quality of life among COPD patients.7,8 In addition, acute 
exacerbations of COPD were found to decrease when com-
paring preintervention and postintervention data after a year 
of medication counseling intervention.8 Similarly, in the UK, 
the patients who were assigned a special 10-week period 
of medication counseling support from their community 
pharmacists were found to be more adherent to their COPD 
medications, to experience better health-related quality of life 
and to use less general practitioner services compared with 
the patients who received standard counseling.9
In Finland, community pharmacists are obliged by law 
to administer verbal medication counseling while dispensing 
medicines to ensure safe and effective pharmacotherapy.16 
In addition to medication counseling, other health promo-
tion–related professional services, such as special asthma, 
smoking cessation, and diabetes services, and medication 
reviews are provided by community pharmacies.17 Since 
1997, the patients with respiratory diseases have been par-
ticularly focused upon by Finnish community pharmacists 
when pharmacies joined the National Asthma Program. In 
participating pharmacies, specific asthma pharmacists were 
named and educated to lead local activities such as education 
and medication counseling.18 In 2017, there were 496 asthma 
pharmacists in 467 community pharmacies (information 
from the Association of Finnish Pharmacies). In parallel 
with the asthma program, a 10-year National Prevention 
and Treatment Program for Chronic Bronchitis and COPD 
was started.19 The asthma program was continued later by 
the National Allergy Program and will be continued until 
2018.20 As a result of these programs, community pharmacists 
have expanded their expertise, eg, with smoking cessation 
services, and pharmacies are increasingly seen as a resource 
for the prevention and treatment of COPD.19,21 During these 
programs, plenty of research has been conducted on the 
prevalence of respiratory diseases and smoking, symptoms, 
hospitalizations, the use of health care services, and costs in 
Finland.3–6,20–22 In addition, some data have been published 
concerning the asthma-related medication counseling in 
community pharmacies, and it was considered to have bet-
ter quality by the asthma pharmacists than by the patients.18 
However, similar to other countries, little is known about the 
knowledge, practices, and perceptions related to COPD and 
its treatment among community pharmacists. The need for 
research in this area is global as community pharmacists in 
any country should be competent and knowledgeable about 
the current care guidelines and should base their medication 
counseling on evidence-based medicine. Research is needed 
to identify both existing practices and needs for development, 
in order to develop COPD medication counseling practices. 
The purpose of this study was to assess community pharma-
cists’ knowledge of COPD, medication counseling practices, 
and perceptions within Finnish community pharmacies.
Materials and methods
study design and population
This was a cross-sectional electronic survey targeting phar-
macists working in community pharmacies in Finland in 
January 2017. One response per pharmacy, representing the 
practice of the whole pharmacy, preferably from a named 
asthma pharmacist, who generally is also aware of COPD, 
was requested. If an asthma pharmacist was not named or not 
available in a pharmacy, a response from another pharmacist 
working in medication counseling was asked for.
The first section of the survey was designed to explore 
pharmacists’ self-assessed level of knowledge of COPD 
and its treatments and measured level of knowledge, by 
factual questions on COPD and its treatments according 
to the Finnish current care guideline.8,9 The first section 
included 10 Likert-type statement questions with a choice 
of four precoded responses (very well, well, poor, and very 
poor) concerning pharmacists’ self-assessed level of COPD 
knowledge related to reasons, symptoms, progress of the 
disease, differences and similarities between asthma and 
COPD, nonpharmacological treatments, inhaled medicinal 
products, other than inhaled medicinal products, symptoms of 
exacerbations, treatment of the exacerbations, and knowledge 
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Community pharmacists’ knowledge, practices, and perceptions of COPD
scale in order to have specific responses from respondents 
by making clear choices for them to self-assess their knowl-
edge, counseling practices, and perceptions. In addition, five 
true/false statements concerning clinical facts of COPD and 
its treatment were included.
The second section of the survey was designed to explore 
pharmacists’ medication counseling practices of the COPD 
patients based on the current care guideline8,9 and the 
United States Pharmacopeia (USP) Medication Counseling 
Behaviour Guideline,23 which is shown to be a valid, reliable, 
and commonly used tool in Finland for evaluating counseling 
practices.24 The USP medication counseling guideline was 
validated and promoted in community pharmacies in Finland 
during the medication counseling development project, at the 
same time as the National Asthma and COPD Programs were 
running.25 In line with the USP guideline, the questions in this 
section were related to different phases (introduction, main 
content, and conclusion phases) of the medication counsel-
ing session. Eight statement questions in the second part of 
the survey were concerned with the introduction phase of 
the medication counseling and covered the following topics 
regarding the COPD patients and treatment of their disease: 
smoking status, current symptoms, previous exacerbations, 
previous medication(s), benefits of previous medication(s), 
drug-related problems of previous medication(s), physical 
habits, and nutritional status. Ten statement questions in the 
second part of the survey were concerned with the main con-
tent phase of the medication counseling when COPD medi-
cine was dispensed to the patient, and covered the following 
topics: advise on smoking cessation and nonsmoking; mode 
of the action(s) of the medicine(s); dosage(s), regimen(s), 
schedule(s), and duration(s) of the medicine(s); possible 
adverse drug reactions; instructions on how to use an inhaler; 
instructions for possible exacerbation(s); advise on physical 
exercise; nutritional instructions; recommendation for flu and 
pneumococcal vaccines; and systematic guidance to seek help 
from a physician when applicable. One statement question in 
the second part of the survey was concerned with the conclu-
sion phase of the medication counseling and how the patient 
was instructed about reliable written information sources 
regarding COPD and its treatment. The 4-point Likert-type 
scale with precoded responses (functions very well, functions 
well, functions poorly, and functions very poorly) was used 
to answer the second section of the survey.
The last section of the survey explored pharmacists’ per-
ceptions of medication counseling of the COPD patients. It 
contained four Likert-type statements with the choice of four 
pre-coded responses (Totally agree, Agree, Disagree, Totally 
Disagree) concerning pharmacists’ perceptions on the following 
statements: if pharmacists consider the medication counseling 
work of a COPD patient as meaningful, whether respondents 
see the role of a pharmacist as important in the chain of different 
health care professionals, and whether pharmacists see if they 
can motivate the COPD patient in the treatment of the disease. 
It was also asked whether the follow-up of COPD patient care 
in the community pharmacy is possible. In addition, demo-
graphic information concerning the pharmacists (gender, year 
of birth, education level, working years, frequency of COPD 
medication counseling, and whether asthma pharmacist or not) 
and the pharmacies (size of the pharmacy, professional special 
services, and tests offered) was collected.
The face and content validity and technical functionalities 
of the survey were pilot-tested by a group of specialists includ-
ing two community pharmacists (BSc and MSc), a social 
pharmacy researcher, a coordinator of the asthma/COPD 
program from the Association of Finnish Pharmacies, and an 
adviser from the Helsinki University for survey application. 
After piloting, some minor changes in the questionnaire were 
made mainly with wording and some technical issues.
Data collection and analysis
The survey was e-mailed from the Association of the Finnish 
Pharmacies to all pharmacies and subsidiary pharmacies. 
In addition, it was e-mailed to all 17 subsidiary pharmacies 
of the Helsinki University Pharmacy and to the University 
Pharmacy of Eastern Finland. Reminders were sent after 
1 week and after 2 weeks from the initial e-mail. In total, 
the survey was sent to 759 e-mail addresses.
Data were quantitatively content-analyzed to compute 
descriptive statistics by using the Statistical Package for Social 
Sciences (SPSS for Windows Version 24.0; IBM Corporation, 
Armonk, NY, USA). The pharmacists’ knowledge and 
medication counseling practices and their associations were 
analyzed by computing descriptive statistics and bivariate 
analyses using Pearson’s χ2 test for categorical variables when 
conditions for the test were met. If the conditions for Pearson’s 
χ2 test were not met, the Fisher’s exact test was used instead. 
The Monte Carlo method was applied to the Fisher’s exact 
test with a confidence level of 99%. In the analyses, p,0.05 
was set as the level of statistical significance.
ethical consideration
The study was conducted in accordance with the guidelines of 
the Finnish National Advisory Board on Research Integrity26 
and was exempt from review and approval by the Helsinki 
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subject research. The completion of the survey by pharma-




Responses were received from 263 pharmacists (response 
rate =35%), including 196 asthma pharmacists (response 
rate =42% among asthma pharmacists). The majority of 
the respondents were female (92%), and the answers were 
received more from bigger pharmacies (.80,000 prescrip-
tions dispensed annually) than from small pharmacies 
(Table 1). Simple medication review, inhalation technique 
assessment service, and comprehensive medication review 
were the most commonly provided professional services in 
community pharmacies where respondents were working 
(Table 1).
Pharmacists’ self-assessed COPD 
knowledge
Over 80% of the respondent pharmacists self-assessed that 
they knew reasons, symptoms, inhaled medicinal products, 
and nonpharmacological treatments for COPD very well or 
well (Table 2). On the other hand, 50% of the pharmacists 
considered that they knew the current care guideline and 
medicinal products, other than inhaled products, poorly or 
very poorly. Pharmacists counseling COPD patients more 
often were more likely to assess their knowledge as being 
better than pharmacists counseling more seldom (p,0.05). 
In addition, pharmacists working in pharmacies providing 
professional services and clinical tests (eg, medication 
reviews, asthma service, diabetes service, COPD assessment 
tests, and microspirometry) were assessed to have better 
COPD-related knowledge than pharmacists working in phar-
macies without those services (p,0.05). There were no other 
significant differences in pharmacists’ self-assessed COPD-
related knowledge according to pharmacists’ and pharmacies’ 
characteristics (eg, age, working years, gender, education, 
pharmacy size, and asthma vs nonasthma pharmacists).
Pharmacists’ measured COPD knowledge
Respondent pharmacists performed well in the knowledge 
test with basic true/false statements concerning clinical facts 
regarding COPD and its treatment. All pharmacists correctly 
knew the following: 1) smoking is the main reason for COPD 
and 2) COPD is not curable. Approximately three of four 
(73%) knew that an inhaled corticosteroid is not always 
Table 1 Characteristics of the respondents, study pharmacies, 
and target population (n=263)
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Community pharmacists’ knowledge, practices, and perceptions of COPD
included in the treatment of the COPD. On the other hand, 
approximately half (46%) of the pharmacists were not famil-
iar that COPD is classified as an important public health issue 
in Finland. In addition, 44% of the pharmacists did not know 
that smoking cessation will stop the progress of the disease. 
The only significant differences between the groups were 
related to pharmacists’ asthma specialization and provision of 
comprehensive medication reviews by the pharmacy. Asthma 
pharmacists had greater knowledge (p,0.05) the role of 
inhaled corticosteroids in the COPD treatment and the impact 
of smoking cessation on the progress of the disease, compared 
with the nonasthma pharmacists. In addition, participants 
working in pharmacies providing comprehensive medication 
reviews had greater knowledge (p,0.05) regarding COPD 
being a national health issue and that a corticosteroid is not 
always included in the treatment, compared with pharmacists 
working in pharmacies without this service.
Medication counseling practices
Introduction phase of the medication counseling
Based on pharmacists’ self-assessments, the most commonly 
discussed issue in the introduction phase of the medication 
counseling was the current symptoms of the patient (Table 3). 
In addition, approximately half of the pharmacists assessed 
that they commonly cover, very well or well, previous 
usage, perceived benefits, and problems of medicines used. 
However, over 75% of the pharmacists responded that they 
usually cover smoking status and physical habits of the 
COPD patients, poorly or very poorly. More than 90% of the 
pharmacists perceived that discussion concerning nutritional 
status of the COPD patient functions usually, poorly, or very 
poorly. Pharmacists who counsel COPD patients more often 
assessed that the clarification of topics related to the patient 
and usage of earlier medicines in the introduction phase, func-
tions better, compared with those who counsel more seldom 
(p,0.05). There were significant differences (p,0.05) in 
some answers according to age and working years: older phar-
macists (born earlier than 1969) and pharmacists with .20 
working years considered that smoking status, nutritional 
status, and physical activities of the patient were clarified 
better compared with younger participants with less working 
experience. Pharmacists working in pharmacies providing 
asthma service considered that the introduction phase of 
counseling functions significantly (p,0.05) better, compared 
with pharmacists working in pharmacies without this service. 
No other differences between groups were identified.
Main content and conclusion phases of the 
medication counseling
The majority of the pharmacists (.90%) assessed that in the 
main content phase of the medication counseling they usually 
cover well or very well instructions concerning how to use 
the inhaler and instructions concerning dosage, timing, and 
maximum dose of the medicine(s) dispensed (Table 3). Other 
topics pharmacists are likely to cover systematically, well or 
very well, include instructions to seek the physician’s help 
when applicable (80% of the pharmacists) and counseling for 
smoking cessation (58% of the pharmacists), whereas the most 
poorly covered issues include guidance for physical exercise 
(20% reported performing well or very well) and nutrition 
counseling (10% reported performing very well or well). 
Concerning the conclusion phase of the medication counsel-
ing, ,20% of the respondents considered that the patient is 
Table 2 Community pharmacists’ self-assessed level of knowledge concerning key issues of COPD and the current care guideline in 
Finland (n=263)
Survey statement Number of responses and percentages to each category
according to self-assessment I know the following key 
issues concerning COPD:
Very well Well Poorly Very poorly
reasons 61 (23%) 178 (68%) 24 (9%) 0 (0%)
symptoms 38 (14.5%) 200 (76%) 25 (9.5%) 0 (0%)
Inhaled medicinal products 34 (13%) 195 (74%) 33 (12.5%) 1 (0.5%)
nonpharmacological treatments (smoking cessation, 
physical exercise, and nutrition)
61 (23%) 161 (61%) 41 (16%) 0 (0%)
similarities and differences between COPD and asthma 28 (10.5%) 173 (66%) 60 (23%) 2 (1%)
Progress of the disease 26 (10%) 170 (64.5%) 66 (25%) 1 (0.5%)
symptoms of exacerbations 21 (8%) 157 (59.5%) 83 (31.5%) 2 (1%)
Treatments of exacerbations 17 (6.5%) 141 (53.5%) 104 (39.5%) 1 (0.5%)
non-inhaled medicinal products 13 (5%) 115 (43.5%) 125 (47.5%) 10 (4%)
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informed, well or very well, about the information sources 
of where to find additional information on COPD medicines 
and care (Table 3). Pharmacists working in pharmacies with 
professional asthma, diabetes, and comprehensive medication 
review services were more likely to rate that their medica-
tion counseling in the main content and conclusion phases 
is performed better, compared with pharmacists working 
in pharmacies without these services (p,0.05). Similarly 
with the introduction phase, pharmacists who were older 
(born earlier than 1969) and with a 20-year working history 
considered that counseling functions significantly (p,0.05) 
better for smoking cessation, physical exercise and nutri-
tion compared with younger participants with less working 
experience. No other significant differences were identified 
in pharmacists’ counseling practices in the main content and 
conclusion phases of the counseling according to pharmacists 
and pharmacy characteristics (eg, gender, education pharmacy 
size, and asthma vs nonasthma pharmacists).
Pharmacists perceptions of counseling 
COPD patients
The majority of pharmacists (90%) perceived counseling of 
COPD patients to be meaningful and agreed (80.5%) that 
pharmacists have an important role in the COPD patients’ 
treatment (Table 4). Three of four agreed that as a pharma-
cist one is able to motivate the COPD patient in the self-
management of the disease. The same number of pharmacists 
(74%) stated that the follow-up of the patients is possible 
at a pharmacy level. Respondents working in pharmacies 
providing comprehensive medication reviews and asthma 
services perceived their role in COPD treatment more posi-
tively (p,0.005) compared with pharmacists from pharma-
cies without these services. Pharmacists counseling more 
often stated also (p,0.05) that medication counseling is 
meaningful, motivating the patient is possible, and the role 
of a pharmacist was seen as more important, compared with 
pharmacists who reported counseling COPD patients more 
seldom. Pharmacists who work in pharmacies where any of the 
professional services (listed in Table 1) are available agreed 
significantly more (p,0.05) that motivating the patient is 
possible, compared with pharmacists from pharmacies without 
these services. In pharmacies where COPD assessment tests 
and asthma tests are used, the pharmacists agreed significantly 
more (p,0.05) that the follow-up of the patients is possible, 
compared with pharmacies without these tests. There were 
no differences in the answers according to age, gender, edu-
cation level, size of the pharmacy, and between asthma and 
nonasthma pharmacists.
Table 3 self-assessment of Finnish community pharmacists (n=263) on how medication counseling of COPD patients functions in 
the introduction, main content, and conclusion phases of the medication counseling session, according to UsP Medication Counseling 
Behaviour Model










Current symptoms 13 (5%) 144 (55%) 94 (35.5%) 12 (4.5%)
Use of earlier medications 15 (5.5%) 136 (52%) 99 (37.5%) 13 (5%)
Benefits of earlier medications 14 (5.5%) 128 (48.5%) 108 (41%) 13 (5%)
Problems with earlier medications 9 (3.5%) 131 (50%) 108 (41%) 15 (5.5%)
Possible earlier exacerbations 6 (2.5%) 88 (33.5%) 146 (55.5%) 23 (8.5%)
Current smoking status 10 (4%) 51 (19%) 162 (62%) 40 (15%)
Physical status and physical habits 6 (2%) 35 (13%) 159 (61%) 63 (24%)
nutritional status 2 (1%) 18 (7%) 156 (59%) 87 (33%)
Main content phase
how to use inhaler 73 (28%) 160 (61%) 24 (9%) 6 (2%)
Dosage, timing, maximum dosage 47 (18%) 186 (70.5%) 25 (9.5%) 5 (2%)
guidance to seek doctor if applicable 61 (23%) 156 (59.5%) 35 (13.5%) 11 (4%)
adverse drug reactions 20 (8%) 140 (53%) 95 (36%) 8 (3%)
Mode of action 16 (6%) 139 (53%) 90 (34%) 18 (7%)
guidance for nonsmoking 32 (12%) 122 (46.5%) 91 (34.5%) 18 (7%)
guidance for vaccinations 30 (11%) 97 (37%) 110 (42%) 26 (10%)
guidance for exacerbation 9 (3.5%) 108 (41%) 130 (49.5%) 16 (6%)
guidance for physical exercise 5 (2%) 49 (18.5%) 154 (58.5%) 55 (21%)
guidance for nutrition 3 (1%) 24 (9%) 160 (61%) 76 (29%)
Conclusion phase
guidance for reliable information sources 5 (2%) 46 (17.5%) 161 (61%) 51 (19.5%)
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Community pharmacists’ knowledge, practices, and perceptions of COPD
Discussion
Although recent reports suggested that pharmacies are recog-
nized as important providers of support for COPD patients,12 
the present study is, according to our understanding, the 
first study concerning community pharmacists’ knowledge, 
practices, and perceptions of medication counseling of COPD 
patients. While community pharmacists’ involvement may be 
beneficial for patients,13–15 it is important that pharmacists are 
familiar with, and base their counseling on, evidence-based 
current care guidelines. The present study demonstrated 
that Finnish community pharmacists perceive themselves as 
important providers of medication counseling and support for 
the COPD patients’ treatment. Although most pharmacists 
self-assessed to have good knowledge on COPD, some gaps 
were identified in both medication counseling practices and 
pharmacists’ knowledge. Similarly with previous studies 
conducted in other European countries, especially the level 
of knowledge about the current care guideline was found to 
be suboptimal. Continuing education is needed not only on 
the content of the current care guidelines, but also on how 
to apply those guidelines into evidence-based medication 
counseling in practice.
This study identified that Finnish pharmacists are familiar 
with reasons and the progress of COPD and with the fact 
that inhaled corticosteroids are not always included in the 
treatment of COPD. On the other hand, only slightly over 
half of the pharmacists knew that COPD is considered as 
a national health issue, which is in line with the awareness 
of the current care guideline, which was, according to self-
assessment, known well or very well by 48% of the partici-
pants. This finding is consistent also with previous research 
on the familiarity of the current care guideline on smoking 
cessation among community pharmacists in Finland: 47% 
of the respondents were familiar with the guideline 4 years 
after its’ original publication and 1 year after its update in 
2007.27 Similarly, a study from England found that the local 
current care guideline or COPD management was read by 
approximately 47% of community pharmacists.28
According to the survey, medication counseling in phar-
macies is more medicinal product driven rather than based 
on the individual status and needs of each COPD patient. 
This is reflected in the finding that, while counseling COPD 
patients, pharmacists more commonly discuss previous use of 
medicines than, eg, smoking status and other lifestyle issues 
(eg, nutrition and physical activity) of the patient. In addi-
tion, the focus on actual medication counseling is on correct, 
safe, and effective use of medicines and in the correct use of 
inhalers. This fulfills the requirements of Finnish legislation 
that requires the community pharmacist to ensure safe and 
effective pharmacotherapy.16 Topics concerning other self-
management of COPD, such as advice on smoking cessation, 
physical exercise, and nutrition, seem not to be the major 
topics in medication counseling even though these are 
important treatment methods of COPD according to global 
and local guidelines.1,8–11 This finding is in line with previous 
findings from community pharmacies from Belgium and the 
Netherlands where medicinal product–related topics such as 
dosage, inhalation technique, and adverse drug reactions are 
discussed more often when counseling COPD patients, while, 
eg, guidance for smoking cessation and physical exercise are 
included less often in medication counseling.29,30 The same 
finding was also seen in a different therapeutic area; medica-
tion counseling concerning antidepressants by community 
pharmacists was more medicinal product driven rather than 
related to, eg, lifestyle changes of the patients.31
Different professional services offered in pharmacies 
seem to have a positive effect on counseling practices. 
Especially asthma service and a comprehensive medication 
review seem to have an impact on more active counseling. 
This finding is in accordance with the Norwegian study 
demonstrating that pharmacists’ participation in the medi-
cation review processes improves the quality of medica-
tion management skills.32 In Finland, the comprehensive 
medication reviews are provided by pharmacists with special 
training.33 Education for comprehensive medication review 
includes topics for clinical interview, which might lead to 
Table 4 Perceptions of the medication counseling and the role of community pharmacists in the COPD treatment by community 
pharmacists in Finland (n=263)




Agree Disagree Totally 
disagree
Counseling work of COPD patients is meaningful 120 (46%) 116 (44%) 27 (10%) 0 (0%)
Pharmacist has an important role in the treatment chain of COPD patients 80 (30.5%) 134 (51%) 44 (16.5%) 5 (2%)
Pharmacist can motivate COPD patients for the self-management of the disease 54 (20.5%) 141 (53.5%) 64 (24.5%) 4 (1.5%)
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a more individual approach in medication counseling work. 
The expertise and communication skills of these specially 
educated pharmacists may be imparted to and adopted by 
other employees in pharmacies where medication reviews 
are provided, which might be seen in the results of this study. 
The survey showed also, interestingly, that older pharmacists 
with more working years self-assessed to perform lifestyle-
related (advise smoking cessation, physical exercise guid-
ance, and nutritional guidance) counseling work better than 
younger colleagues in both the introduction phase and the 
main content phase of the counseling.
Practice implications and future studies
In the strategy for rational use of medicines by the Finnish 
Medicines Agency, one strategic goal is that health care 
professionals utilize reliable medicines information sources 
and base their medication counseling on evidence-based 
current care guidelines.34 From this point of view, wider 
awareness of the COPD current care guideline and its bet-
ter implementation to medication counseling in community 
pharmacies should be further developed. This is supported 
by the Finnish study where it was shown that pharmacists 
who knew the current care guideline on smoking cessation 
better, used its information more widely for the benefit of the 
patients.27 This study showed that medication counseling is 
medicinal product driven, and it should be developed to be 
more tailored and holistic and based on each patient’s indi-
vidual needs. To reach this goal, a nationwide development 
project has already been started for medication counseling 
in community pharmacists led by cooperative groups of dif-
ferent organizations (oral information from the Association 
of Finnish Pharmacies). The project is a continuation of 
earlier projects for developing medication counseling35 and 
implementing medication review as a professional service in 
community pharmacies in Finland.36 The study also indicated 
that professional services might have a positive impact on 
counseling practices and pharmacists’ COPD knowledge. 
This might be due to the special education and knowledge 
needed for these professional services. However, continuing 
education is still needed to confirm that pharmacists have the 
competency and skills to take a more holistic approach to 
counseling COPD patients in practice and to be more aware 
of current care guidelines. The education should include 
aspects concerning the importance of smoking cessation, 
physical exercise, and medication counseling in relation to 
each patient’s individual status and individual needs so that 
pharmacists are able to communicate and manage these issues 
with COPD patients.
For the purposes of developing pharmacy education 
on COPD and COPD counseling, further quantitative and 
qualitative studies may be complemented from both the 
pharmacists and patients’ perspectives. More information is 
needed about patient perceptions of their information needs 
of COPD that should be taken into account while counseling 
patients in pharmacies. This would be highly important in 
order to better support self-management of the patients by 
community pharmacists. In addition, the survey used in this 
study, based on USP’s medication counseling model and 
modified according to the local current care guideline, could 
be studied to evaluate its comprehensiveness, especially from 
the COPD patients’ perspectives, and to evaluate the content 
validity of the survey. Longitudinal studies are required to 
explore how COPD counseling practices change over time 
and to assess the implementation of the recent development 
project on medication counseling, especially from the per-
spective of this patient group. In addition, the effect and cost-
effectiveness of medication counseling of COPD patients 
need further investigation. Longitudinal studies concerning 
practices of medication counseling could also be made with a 
pseudo customer method to increase the objectivity. Pseudo 
customers have been used in Finland earlier also in connec-
tion with studies concerning medication counseling practices 
in community pharmacies.37 Furthermore, the finding of this 
study, concerning older pharmacists with more working years 
being more active in counseling regarding lifestyle-related 
topics (eg, smoking, physical activity, and nutritional status) 
of COPD patients, could be further studied, eg, by a pseudo 
customer method to assess whether it is a real phenomenon 
or only self-perception by older pharmacists.
strengths and limitations
To our knowledge, this is the first specific study concerning 
the knowledge of COPD, medication counseling practices, 
and perceptions concerning medication counseling of COPD 
patients among community pharmacists. The survey was 
sent to all Finnish community pharmacies, and thus, the 
result represents the nationwide situation. In addition, in 
terms of gender, educational level, age, and working years, 
the pharmacists who responded to this survey represent very 
well the general pharmacist population in Finland. However, 
respondents were not likely to have been representatives of 
all Finnish pharmacists. It is possible that the perspective of 
pharmacists working in smaller pharmacies were not fully 
captured.
On the other hand, the survey was preferentially given 
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Community pharmacists’ knowledge, practices, and perceptions of COPD
pharmacists, the response rate was 42%. Therefore, the 
answers represent more the nationwide views of asthma 
pharmacists than the general pharmacist population in Fin-
land. The face and content validity of the survey instrument 
was examined among experts including general pharmacists; 
however, it may have benefited by also including some 
asthma pharmacists. The response rates in recent studies in 
Finnish community pharmacies (sent by e-mail) have yielded 
response rates between 45% and 55%.38,39 The response rate 
among asthma pharmacists in this study is about the same.
Due to the use of a Likert-type scale in the survey, the 
data have been analyzed by using bivariate analysis. This 
may increase the type I error risk, which should be recog-
nized when interpreting the results relating to the associa-
tions between variables. However, descriptive statistics and 
bivariate tests provided a valid and reliable overview of the 
key study questions: pharmacists’ self-assessed knowledge 
of COPD, medication counseling practices, and perceptions 
of counseling of COPD patients. Further studies are needed 
in order to provide more comprehensive understanding of 
demographic and other factors associated with pharma-
cist knowledge, practices, and perceptions of counseling 
COPD patients.
Conclusion
Our study showed that community pharmacists perceived that 
they have an important role in counseling COPD patients and 
supporting their self-management of the disease. Pharmacists 
self-assessed that they have good knowledge about COPD 
and its treatment, and this was also evident concerning the 
basic facts of COPD and its treatment. However, some gaps 
were identified in the pharmacists’ knowledge on the current 
care guideline and in the status of COPD as a national public 
health issue. COPD medication counseling was found to be 
medicinal product driven in all phases of the medication 
counseling, and important lifestyle changes such as smoking 
cessation and physical exercise as nonpharmacological 
treatments of COPD are not actively screened or counseled. 
Medication counseling is not very individual according to a 
patient’s status and needs. Continuing education is needed to 
implement the evidence-based current care guideline better 
in the medication counseling practice and to promote a more 
holistic and individual approach in counseling COPD patients 
in community pharmacies.
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